Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
Zhiyuan Chen, Ming Shi, Li Xia Peng, et al.
Journal of Translational Medicine (2012) Vol. 10, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer, Thomas E. Hutson, Hilary Glen, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 15, pp. 1473-1482
Open Access | Times Cited: 882
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
Asmaa El-Kenawi, Azza B. El‐Remessy
British Journal of Pharmacology (2013) Vol. 170, Iss. 4, pp. 712-729
Open Access | Times Cited: 230
A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation
Xinjian Li, Xu Qian, Li-Xia Peng, et al.
Nature Cell Biology (2016) Vol. 18, Iss. 5, pp. 561-571
Open Access | Times Cited: 175
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling
Young Kwang Chae, Su Yun Chung, Andrew A. Davis, et al.
Oncotarget (2015) Vol. 6, Iss. 35, pp. 37117-37134
Open Access | Times Cited: 101
Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
Gottfried E. Konecny, Teodora Kolarova, Neil A. O’Brien, et al.
Molecular Cancer Therapeutics (2013) Vol. 12, Iss. 5, pp. 632-642
Open Access | Times Cited: 70
Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity
Camillo Porta, Palma Giglione, Wanda Liguigli, et al.
Future Oncology (2015) Vol. 11, Iss. 1, pp. 39-50
Closed Access | Times Cited: 54
A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients
Zhi-yuan Chen, Wenzhuo He, Li‐Xia Peng, et al.
International Journal of Cancer (2014) Vol. 136, Iss. 3, pp. 584-592
Open Access | Times Cited: 45
FGF-2-mediated FGFR1 signaling in human microvascular endothelial cells is activated by vaccarin to promote angiogenesis
Hai‐Jian Sun, Weiwei Cai, Leilei Gong, et al.
Biomedicine & Pharmacotherapy (2017) Vol. 95, pp. 144-152
Closed Access | Times Cited: 45
Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET
Elena Hernández-Agudo, Tamara Mondejar, María Luisa Soto‐Montenegro, et al.
Molecular Oncology (2015) Vol. 10, Iss. 5, pp. 704-718
Open Access | Times Cited: 38
Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Shilpi Agrawal, Sanhita Maity, Zeina Alraawi, et al.
Current Drug Targets (2020) Vol. 22, Iss. 2, pp. 214-240
Closed Access | Times Cited: 28
Hepatic Growth Factor as a Potential Biomarker for Lung Adenocarcinoma: A Multimodal Study
Mengxuan Sun, Yang Yu, Haoyu Zhu, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 208-208
Open Access
Correlation between prognostic markers and clinical parameters in hepatocellular carcinoma: Pathophysiological aspects to therapeutic targets
Saira Rafaqat, Iqra Noshair, Momina Shahid, et al.
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 5
Open Access
MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way
Shiji Fang, Liyun Zheng, Xiaoxiao Chen, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1500-1518
Open Access | Times Cited: 9
Approaches Targeting the FGF–FGFR System: a Review of the Recent Patent Literature and Associated Advanced Therapeutic Agents
Corentin Herbert, Gilbert Lassalle, Chantal Alcouffe, et al.
Pharmaceutical Patent Analyst (2014) Vol. 3, Iss. 6, pp. 585-612
Closed Access | Times Cited: 23
A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
Jin-Ho Kang, Yoon Ji Choi, Bo Yeon Seo, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 21
Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts
Z. Y. Chen, Wei Wei, Z-X Guo, et al.
British Journal of Cancer (2013) Vol. 110, Iss. 3, pp. 733-740
Open Access | Times Cited: 22
Bioinformatics Analysis Combined With Experiments Predicts PUDP as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Through Its Interaction With Tumor Microenvironment
Jiahao Yu, Weirui Zhang, Dawei Ding, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
A murine–human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro
Guipeng Ding, Ximin Chen, Jin Zhu, et al.
Cytotechnology (2013) Vol. 66, Iss. 3, pp. 395-411
Open Access | Times Cited: 4
Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?
James J. Harding, Ghassan K. Abou‐Alfa
PubMed (2014)
Closed Access | Times Cited: 3
Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives
Tarun Sahu, Arundhati Mehta, Henu Kumar Verma, et al.
Elsevier eBooks (2022), pp. 227-253
Closed Access
Page 1

Scroll to top